Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266835 | 1.00 | CYP3A4 (0.64) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL28005407 | 0.79 | MAOA (0.53) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL7698974 | 0.77 | CYP1A2 (0.63) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL4780554 | 0.77 | KMT2A (0.53) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL2565537 | 0.77 | TRPA1 (0.50) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL4958276 | 0.77 | KMT2A (0.50) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL8649259 | 0.73 | CYP1A2 (0.51) | CYP3A4CYP2C9HIF1AHSD17B10CYP1A2 | |
| SCHEMBL3280497 | 0.71 | — | — | |
| Azobenzene SCHEMBL182577 | 0.71 | ALDH1A1 (0.92) | HSD17B10CYP1A2KMT2AMEN1MAPT | |
| Azobenzene SCHEMBL182578 | 0.71 | ALDH1A1 (0.92) | HSD17B10CYP1A2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010011642-A2 | METHODS AND COMPOSITIONS USING SPLICING REGULATORY PROTEINS INVOLVED IN TUMOR SUPPRESSION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-01-28 | — | — | WO | claimed |
| EP-4366739-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023279193-A2 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-01-12 | — | — | WO | disclosed |
| US-9127078-B2 | Methods and compositions using splicing regulatory proteins involved in tumor suppression | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-09-08 | — | — | US | disclosed |
| US-20110177967-A1 | METHODS AND COMPOSITIONS USING SPLICING REGULATORY PROTEINS INVOLVED IN TUMOR SUPPRESSION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010011642-A2 | METHODS AND COMPOSITIONS USING SPLICING REGULATORY PROTEINS INVOLVED IN TUMOR SUPPRESSION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20080124732-A1 | METHOD FOR OPTICAL MEASUREMENT OF MULTI-STRANDED NUCLEIC ACID | FUJIFILM CORPORATION | 2008-05-29 | — | — | US | disclosed |
| EP-1889880-A2 | Method for optical measurement of multi-stranded nucleic acid | FUJIFILM Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1362894-B1 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJIFILM CORP (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20060264381-A1 | Methods of treating obsessive compulsive disorder | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-23 | — | — | US | disclosed |
| US-20050112770-A1 | Method for optical measurement of multi-stranded nucleic acid | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| EP-1267869-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TOLERANCE AND DEPENDANCE | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| EP-1362894-A2 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJI PHOTO FILM CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-1267869-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TOLERANCE AND DEPENDANCE | GLAXO GROUP LIMITED (GB) | 2003-01-02 | — | — | EP | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001066113-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING TOLERANCE AND DEPENDENCY | GLAXO GROUP LIMITED (GB) | 2001-09-13 | — | — | WO | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264381-A1 | Methods of treating obsessive compulsive disorder | OXTR, MECP2, GRM5 | CYP3A4 4880/4885CYP2C9 4832/4885HIF1A 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.